News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
331,293 Results
Type
Article (19650)
Company Profile (139)
Press Release (311504)
Section
Business (106414)
Career Advice (870)
Deals (18902)
Drug Delivery (90)
Drug Development (50705)
Employer Resources (79)
FDA (7673)
Job Trends (7859)
News (187291)
Policy (17400)
Tag
Academia (737)
Alliances (27971)
Alzheimer's disease (561)
Approvals (7642)
Artificial intelligence (81)
Bankruptcy (171)
Best Places to Work (5643)
Biosimilars (67)
Biotechnology (62)
Cancer (546)
Cardiovascular disease (60)
Career advice (707)
Cell therapy (83)
Clinical research (41787)
Collaboration (213)
Compensation (69)
COVID-19 (1078)
C-suite (60)
Data (622)
Diabetes (94)
Diagnostics (1797)
Drug pricing (91)
Earnings (38753)
Employer resources (73)
Events (48022)
Executive appointments (199)
FDA (7937)
Funding (160)
Gene therapy (87)
GLP-1 (485)
Government (1808)
Healthcare (6014)
Infectious disease (1126)
Inflammatory bowel disease (67)
Interviews (114)
IPO (7427)
Job creations (2438)
Job search strategy (648)
Layoffs (252)
Legal (4097)
Lung cancer (96)
Manufacturing (129)
Medical device (2118)
Medtech (2121)
Mergers & acquisitions (11515)
Metabolic disorders (326)
Neuroscience (727)
NextGen Class of 2024 (2432)
Non-profit (918)
Northern California (671)
Obesity (210)
Opinion (175)
Patents (70)
People (33216)
Pharmaceutical (75)
Phase I (13024)
Phase II (17697)
Phase III (14230)
Pipeline (284)
Podcasts (56)
Policy (70)
Postmarket research (1612)
Preclinical (4580)
Radiopharmaceuticals (158)
Rare diseases (138)
Real estate (3224)
Regulatory (12198)
Research institute (824)
Resumes & cover letters (138)
Southern California (621)
Startups (2043)
United States (6190)
Vaccines (212)
Weight loss (184)
Date
Last 7 days (330)
Last 30 days (1754)
Last 365 days (18126)
2024 (16607)
2023 (19857)
2022 (26257)
2021 (27029)
2020 (25326)
2019 (20612)
2018 (15969)
2017 (17411)
2016 (16295)
2015 (18971)
2014 (14905)
2013 (12637)
2012 (13613)
2011 (13914)
2010 (12819)
Location
Africa (407)
Asia (24714)
Australia (3162)
California (1510)
Canada (771)
China (147)
Colorado (67)
Connecticut (60)
Europe (50651)
Florida (217)
Illinois (147)
Indiana (116)
Japan (56)
Maryland (228)
Massachusetts (1276)
Minnesota (95)
New Jersey (580)
New York (440)
North Carolina (359)
Northern California (671)
Ohio (71)
Pennsylvania (374)
South America (607)
Southern California (621)
Texas (201)
Washington State (145)
331,293 Results for "vertice pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
Business
Zylö announces the creation and spinout of Atticus Pharma Inc.
Zylö recently effected a spinout of Atticus Pharma Inc., whose mission is to unlock the value of the Z-pod ® topical delivery platform in the pharmaceutical vertical.
April 17, 2024
·
3 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Press Releases
Biomerics Launches its New Vertically Integrated Metal Injection Molding (MIM) Services
October 17, 2024
·
3 min read
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced leadership from its business verticals will be presenting at, and participating in, the following conferences.
March 28, 2024
·
5 min read
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here,
BioSpace
examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
·
5 min read
·
Mollie Barnes
1 of 33,130
Next
